business

Aim is to prevent rampant use of antibiotics: P Lilladher

Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.

first published: Mar 14, 2016 09:18 am